We are pleased to announce that Professor Serge Mignani will be back to the Madeira Chemistry Research Centre (CQM), in June 2023, to offer us a new seminar about cancer, nanomedicine, and drug discovery.
Cancer represents one of the leading causes of death and morbidity with a high complex pathophysiology. Traditionally, cancer therapies include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multi-drug resistance advance a substantial challenge for favorable cancer treatment. The main objective of nanomedicine research is the development of nanoparticles as drug delivery systems or as nanodrugs to tackle diseases, such as cancers, which are a leading cause of death within developed nations. Nanotechnology, specially the nanocarrier approach for drug delivery, has attracted much attention in the development of cancer treatment aimed to avoid, for instance, the systemic toxicities of classical conventional cytotoxic drugs. The specific advantages of these nanoparticles are biocompatibility, reduced toxicity, overcome multidrug resistance, more excellent stability, enhanced permeability and retention effect, and precise targeting. The nanotherapeutic technologies currently used for anticancer drug delivery therapies are as follows: polymer-drug conjugates, polymer micelles, liposomes, dendrons, dendrimers, mesoporous silica, albumin nanoparticles, metallic nanoparticles, chitosan nanoparticles etc. Results from pre-clinical and clinical trials using nanoparticles are encouraging, suggesting that nanoparticles provide strong opportunities to design and tune up particular properties of drugs (nanocarrier approach), and to develop nanodevices as drugs per se. Such interventions are not possible with other types of therapeutics and have thus fueled much enthusiasm with regards the wealth of opportunities afforded by this emerging field of nanoscience in oncology.
The announced seminar "Nanomedicine in oncology drug discovery: Main drug development aspects" will be held at the University of Madeira (Sala do Senado), on 07th of June of 2023, 15h00. The focus of this presentation will be to analyze the current main challenges and remaining issues facing the infinite armada in systematic cancer nanotherapy for oncological implications in cancer treatment. Then, the future of cancer nanomedicine including challenges in clinical translation will be summarized and analyzed with regards of nano-formulations which have created brand new perspectives for cancer treatment. However, the number of nano-drugs that are approved has not much amplified over the years.
Professor Serge Mignani, from the Centre d’Etudes et de Recherche sur le Médicament de Normandie (France) was, for more than 40 years, researcher in one of the biggest pharmaceutical industries, Rhône-Poulenc, currently named Sanofi, where he served as director of the Medical Chemistry Department. He is now a consultant for several big and medium pharmaceutical industries (France and USA) and Institutes (France, China, Portugal, and India). He collaborates with the University of Madeira since 2013 and is officially a CQM researcher since 2017, being responsible for the Medicinal Chemistry area and nanomedicine translation activities.
|Registration deadline is the 01st of June of 2023.|
|Registration form (Closed!)|